GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (FRA:0CB) » Definitions » Debt-to-Revenue

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Debt-to-Revenue : N/A (As of Oct. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Oxford Cannabinoid Technologies Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Oxford Cannabinoid Technologies Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was €0.00 Mil. Oxford Cannabinoid Technologies Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was €0.00 Mil. Oxford Cannabinoid Technologies Holdings's annualized Revenue for the quarter that ended in Oct. 2023 was €0.00 Mil.


Oxford Cannabinoid Technologies Holdings Debt-to-Revenue Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings Debt-to-Revenue Chart

Oxford Cannabinoid Technologies Holdings Annual Data
Trend May18 May19 May20 May21 Apr23
Debt-to-Revenue
N/A N/A N/A N/A N/A

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
May19 Nov19 May20 Nov20 May21 Nov21 Oct22 Apr23 Oct23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Oxford Cannabinoid Technologies Holdings's Debt-to-Revenue

For the Biotechnology subindustry, Oxford Cannabinoid Technologies Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford Cannabinoid Technologies Holdings's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford Cannabinoid Technologies Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oxford Cannabinoid Technologies Holdings's Debt-to-Revenue falls into.



Oxford Cannabinoid Technologies Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Oxford Cannabinoid Technologies Holdings's Debt-to-Revenue for the fiscal year that ended in Apr. 2023 is calculated as

Oxford Cannabinoid Technologies Holdings's annualized Debt-to-Revenue for the quarter that ended in Oct. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Oct. 2023) Revenue data.


Oxford Cannabinoid Technologies Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oxford Cannabinoid Technologies Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Cannabinoid Technologies Holdings (FRA:0CB) Business Description

Traded in Other Exchanges
Address
267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Headlines

No Headlines